SCHEMBL18172285

SCHEMBL18172285

Cc1noc(C)c1-c1cnc(NCC(=O)OC(C)(C)C)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.49
CREBBP Q92793 5/20 0.47
ATAD2 Q6PL18 1/20 0.42
BRD2 P25440 3/20 0.38
AAK1 Q2M2I8 1/20 0.38
GABRA5 P31644 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20061676 0.85 ATAD2 (0.44) BRD4CREBBPATAD2BRD2ALDH1A1
SCHEMBL18172290 0.84 BRD4 (0.47) BRD4CREBBPBRD2AAK1GABRA5
SCHEMBL19726803 0.74 BRD4 (0.51) BRD4ATAD2BRD2ALDH1A1LMNA
SCHEMBL18174242 0.71 BRD4 (0.51) BRD4CREBBPBRD2AAK1LMNA
SCHEMBL15836986 0.70 BRD4 (0.54) BRD4CREBBPATAD2BRD2
SCHEMBL19231225 0.69 BRD4 (0.50) BRD4ATAD2BRD2
SCHEMBL18172284 0.69 CYP1A2 (0.62) BRD4CREBBPBRD2ALDH1A1LMNA
SCHEMBL18172283 0.69 CYP1A2 (0.48) BRD4ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL17807840 0.69 BRD4 (0.52) BRD4CREBBPATAD2BRD2CYP1A2
SCHEMBL18181282 0.68 ERN1 (0.42) BRD4CREBBPBRD2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107750251-B Isoxazolyl-substituted imidazopyridines 塞尔森瑞科有限责任公司 2020-09-01 CN disclosed
US-10428065-B2 Isoxazolyl substituted imidazopyridines CELLCENTRIC LTD (GB) 2019-10-01 US disclosed
EP-3286188-B1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES CELLCENTRIC LTD (GB) 2019-03-20 EP disclosed
US-20180105519-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES CELLCENTRIC LTD (GB) 2018-04-19 US disclosed
EP-3286188-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES Cellcentric Ltd (GB) 2018-02-28 EP disclosed
WO-2016170323-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES CELLCENTRIC LTD (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105519-A1 ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES EP300, HDAC3, HDAC1 BRD4 17/4885CREBBP 16/4885ATAD2 1406/4885
US-10428065-B2 Isoxazolyl substituted imidazopyridines EP300, HDAC3, HDAC1 BRD4 17/4885CREBBP 16/4885ATAD2 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.